ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation.

X. Cheng,1 M. Stedman,1 W. Kim,2 J. Tan.1

1Division of Nephrology, Stanford University, Palo Alto, CA
2Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA.

Meeting: 2016 American Transplant Congress

Abstract number: 78

Keywords: Allocation, Kidney/liver transplantation, Outcome

Session Information

Date: Sunday, June 12, 2016

Session Name: Concurrent Session: The Kidney in Liver Transplantation

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:54pm-3:06pm

Location: Room 302

Related Abstracts
  • The Importance of KDPI in Simultaneous Liver and Kidney Transplant.
  • Simultaneous Liver-Kidney Transplantation Using Donors with Standard and Extended Criteria Kidneys

The number of simultaneous liver-kidney transplants (SLKT) for end-stage liver disease (ESLD) with renal failure is rising. The overall utility of kidneys used in this setting has not been quantified. We hypothesize:

1) Kidneys allocated as SLKT have shorter graft survival than do kidneys allocated as kidney (Ki) or kidney-pancreas (KP) transplants.

2) Each kidney, if allocated as Ki/KP, would offer a high benefit as measured by life-year-from-transplant (LYFT).

Methods

Deceased donor kidney pairs from 1/1/1995 through 12/3/2014, in which one kidney is utilized in SLKT and the other in kidney (Ki) or kidney-pancreas (KP) transplantation, were identified in Scientific Registry of Transplant Recipients. Excluded were pediatric recipients, other multi-organ transplants, SLKT for metabolic disorders or amyloidosis, and SLKT with pre-transplant dialysis duration >90 days.

The primary outcome was 10-year mean graft survival by transplant type, estimated from flexible parametric models restricted to 10-year follow-ups adjusted for donor and recipient characteristics. Graft survival was partitioned into graft failure and death using a competing risk framework. Expected LYFT per kidney was calculated as a weighted average based on Wolfe et al.'s projections and baseline characteristics of our matched Ki/KP cohort.

Results

We matched 3299 SLKT cases to 2617 Ki and 682 KP cases. Kidneys allocated to KP/SLKT pairs were of higher quality than kidneys allocated to Ki/SLKT pairs (median KDRI 0.75 vs 0.88, p<0.001). Compared to Ki and KP recipients, SLKT recipients were more likely to be male, white, older, have a private insurer, and not be on dialysis at time transplant (<0.001).

Median graft survival exceeds 9 years in all transplant groups. SLKT resulted in 1.24 (95% C.I. 0.79-1.69) and 0.46 (95% C.I. -0.61-1.52) fewer years per graft compared to Ki and KP. Graft loss was driven by death in SLKT and by graft failure in Ki/KP. The median expected LYFT per kidney used in SLKT was 5.99 if allocated to a Ki and 9.31 if allocated to a KP candidate.

Conclusion

In the decade post-transplant, kidneys allocated to SLKT for renal failure in ESLD experience a modestly reduced survival compared to those allocated to Ki. The potential LYFT to be gained per kidney for Ki/KP candidates is substantial. Further studies are needed to quantify the benefit of SLKT over liver transplant alone.

CITATION INFORMATION: Cheng X, Stedman M, Kim W, Tan J. Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cheng X, Stedman M, Kim W, Tan J. Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/utility-in-treating-renal-failure-in-end-stage-liver-disease-with-simultaneous-liver-kidney-transplantation/. Accessed March 9, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.